Our vision includes healthcare redesign models that are unique in the industry.
Flex Therapy Pricing:
As we work on Orphan Drugs, we realized that the current pricing models for clients/patients are absurd. For example, Orphan Drugs have an average annual cost of $32,000, and more than a third of drugs with Orphan indications cost more than $100,000 annually. High-cost therapies are generally prescribed for a small portion of patients who can afford the product.
All terminal patients should be able to afford the therapy that their doctor prescribes. Verax plans to introduce a new pricing model (Flex Therapy Pricing - "FTP") that discounts the price of the therapy based on household income. We believe that no terminal patient should be asked to pay more than 20% of their annual gross income for our products.
Here are some economic examples:
Current Orphan Drug Pricing Models*
200,000 terminal patients.
Product price: $10,000 per month.
Patients that can afford the product per year: 1,000
Annual gross income potential from product sales: $120M
Verax Flex Therapy Pricing (TM)*
200,000 terminal patients.
The product price ranges from $1,000 to $10,000 per month.
Patients that can afford the product per year: 145,000
Annual gross income potential from product sales: $6.6B
As you can see, the Flex Therapy Pricing is not only good for patients, it is good for the bottom line of our investors.
* The content on this page contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available. Forward-looking statements include information about our current expectations for future events, including potential results of operations, the timing of clinical trials, the timing of regulatory filings and approvals, the timing and outcomes of regulatory or intellectual property decisions, demand for our commercially available products and products in development, and the clinical benefits, safety profile, and commercial potential and potential pricing of any product candidates.
These forward-looking statements are subject to known and unknown risks, uncertainties, and assumptions, including those associated with the COVID-19 pandemic, and other factors that could cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation. You should read our most recent filings with the Securities and Exchange Commission including our Transition Report on Form 10-K and our Quarterly Reports on Form 10-Q, including the Risk Factors set forth therein and the exhibits thereto, and our subsequent filings with the Securities and Exchange Commission, completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.